Brief: Calliditas Announces Primary Endpoint Successfully Met In Phase 3 Nefigard Trial Evaluating Nefecon In IGA Nephropathy

Calliditas Therapeutics AB

12/03/2023 17:34

March 12 (Reuters) - Calliditas Therapeutics AB
 CALTX.ST :
    * CALLIDITAS ANNOUNCES PRIMARY ENDPOINT SUCCESSFULLY MET IN
PHASE
3 NEFIGARD TRIAL EVALUATING NEFECON ®  IN IGA NEPHROPATHY
    * CALLIDITAS THERAPEUTICS AB - SUPPORTIVE 2-YEAR TOTAL SLOPE
ANALYSES WERE SIGNIFICANT AND CLINICALLY MEANINGFUL REFLECTING A
SUSTAINED TREATMENT BENEFIT
    * CALLIDITAS THERAPEUTICS- EGFR BENEFIT WAS OBSERVED ACROSS
ENTIRE
STUDY POPULATION, IRRESPECTIVE OF URINE PROTEIN-TO-CREATININE
RATIO (UPCR) BASELINE
    * CALLIDITAS THERAPEUTICS- UPCR REDUCTIONS OBSERVED WERE
DURABLE,
REFLECTING LASTING TREATMENT EFFECT DURING 15-MONTH FOLLOW-UP
PERIOD OFF TREATMENT
    * CALLIDITAS THERAPEUTICS- PLANS TO FILE FOR FULL APPROVAL
FROM
FDA, AND SUPPORT FILING FOR FULL APPROVAL WITH EC AND UK MHRA
DURING 2023

Source text for Eikon:  ID:nWkr4gR9Wn 
Further company coverage:  CALTX.ST 

 ((reuters.briefs@thomsonreuters.com;))